According to Liu, such growing markets in precision medicine include direct-to-consumer DNA tests, drug sensitivity testing and cancer treatment.
SINGAPORE (Feb 5): Emerging areas of precision medicine could transform loss-making healthcare group Clearbridge Health into a “potential unicorn in the making”, according to Tayrona Financial, the independent equity research house formerly known as NRA Capital.
“We see high growth potential for the company as doctors increasingly customise treatments to patients’ genetic composition,” says analyst Liu Jinshu in a Jan 31 report. “With its network across Asia, Clearbridge is positioning itself to tap on this trend over the next five to ten years.”
